Peripheral CB1 Receptor Antagonists for Obesity Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current obesity treatments are ineffective in maintaining weight loss over time and are associated with significant side effects, and there is a need for safer medications that target CB1 receptors in peripheral tissues to address obesity, diabetes, and cardiometabolic disorders without CNS adverse effects.

Innovation Solution

Development of novel pyrazoline compounds that act as CB1 receptor antagonists/inverse agonists, designed to preferentially target peripheral tissues while minimizing brain penetration to reduce CNS side effects, thereby providing therapeutic benefits for obesity, diabetes, and cardiometabolic disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current obesity treatments (CNS appetite suppressants and gut lipase inhibitors) are used, then weight loss is achieved, but the weight loss is not maintained over time and significant side effects occur

Engineering Contradiction:

Improveweight loss maintenanceVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds that selectively target CB1 receptors in peripheral tissues (adipose tissue, liver, muscle, gastrointestinal tract) while avoiding CNS penetration. This is achieved through molecular structure design that confers peripheral selectivity, allowing the drug to act locally in metabolic tissues without affecting brain CB1 receptors, thereby maintaining weight loss efficacy while eliminating CNS-related side effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the CB1 receptor targeting function into two distinct compartments: peripheral tissue targeting for metabolic regulation and CNS exclusion for side effect prevention. This segmentation is achieved through pharmacokinetic design that allows the compound to access peripheral tissues while being excluded from the brain, effectively separating the therapeutic action from the harmful effects

Inventive Principle:

Principle #1Segmentation

2Object-affected harmful factors

If CB1 receptor antagonists are designed to target peripheral tissues, then CNS side effects are reduced, but selective targeting of peripheral CB1 receptors must be achieved

Engineering Contradiction:

ImproveCNS side effectsVSAvoidcompound design complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent employs parameter changes by modifying molecular properties (lipophilicity, molecular weight, structural features) to control blood-brain barrier penetration. By adjusting these physicochemical parameters, the compounds achieve optimal peripheral tissue distribution while maintaining low CNS exposure, balancing selectivity requirements with pharmacokinetic constraints

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS7666889B2Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Publication Date: 2010.02.23 JENRIN DISCOVERY LLC

AI summary

The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.